Results of a Trial Comparing Cabozantinib and Sunitinib in mRCC

M. Michele Blackwood, MD, FACS, provided an overview of the significant advancements with personalized medicine with genomic testing in the breast cancer space.

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer.

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

Savita Dandapani, MD, PhD, discussed combining radium-223 and SBRT for metastatic castration-sensitive prostate cancer.

In an interview, Prithviraj Bose, MD, discussed the multiple JAK inhibitors available for the treatment of patients with myeloproliferative neoplasms.